Navigation Links
EuroPCR 2014 examines vascular response and long-term safety of bioresorbable scaffolds
Date:5/22/2014

22 May 2014, Paris, France: At EuroPCR 2014 yesterday, experts discussed the development in evidence for bioresorbable vascular scaffolds, which represent an era of vascular restoration in interventional cardiology. The available data were analysed and participants heard that bioresorbable fixed strut vascular scaffolds are associated with increased acute thrombogenicity due to flow disturbances. This means that patients who are implanted with these devices need to receive ongoing dual antiplatelet therapy, and the strategy is under discussion. The panellists also pointed out that endothelialisation is further delayed when these devices are used compared with when thin strut drug-eluting stents are used.

Tan Huay Cheem, National University Heart Centre, Singapore, said: I think one of the greatest attractions of bioresorbable vascular scaffolds is the idea that normal vasofunction will eventually be restored. There is some evidence from imaging data to show that the plaque is modified alongside the stent dissolving. There is also positive remodelling taking place, and this vascular response is one of the most exciting aspects of the technology.

The diversity of devices that are approaching the market was also emphasised. Michael Joner, CEO, CVPath Institute, Gaithersburg, USA, said: There is no uniformity in these devices and no class effect. Every device needs to be assessed carefully and individually. The inflammatory response associated with these devices depends on the pace of degradation, so we need to assess how they degrade over time, and this has important implications for patient safety.

The long-term safety of bioresorbable vascular scaffolds will depend on various things: if we can see that arterial healing occurs over time; if full degradation occurs in the absence of excess inflammation and if we do not see too much positive remodelling, then these devices can be very beneficial to patient care, Joner added.

I think the technology is very interesting, but the bar that has been set by drug-eluting stents is very high and bioresorbable vascular scaffolds will need to match this, especially with regard to strut thickness and deliverability, said Prof Chaim Lotan, Head of the Cardiovascular Insitute, Hadassah University Hospital, Jerusalem, Israel.

Lotan also commented on the lack of long-term safety data being available. We need follow-up data of more than five years duration, possibly up to 10 years, because our previous experience with bare metal stents and drug-eluting stents has shown that we still see changes up to seven years. So we await long-term data for bioresorbable vascular scaffolds with regard to device behaviour and degradation patterns. We have seen cases where the stent has not yet degraded after three years and this could pose a problem for patients. Will the degradation occur as planned? Will the struts be apposed? Will we see late events such as thrombosis? All these are unanswered questions, he said.

Robert-Jan van Geuns, University of Rotterdam, The Netherlands, pointed to the potential advantages of using bioresorbable vascular scaffolds. In general, the data emerging are in line with the theory behind these devices: that vascular restoration therapy is going to heal vessels better than metallic stents. The long-term data has been demonstrated in non-complex patients, and we see that these patients do very well. We still need more data in more complex patients; there are now some non-randomised data available that are out to six-months, but we have to wait for the evidence in more complex patients before we can advocate the use of these devices in such patients, he said.


'/>"/>

Contact: Isabelle Uzielli
iuzielli@europcr.com
EuroPCR
Source:Eurekalert

Related medicine news :

1. CRF will Provide updates on several key cardiovascular trials at EuroPCR
2. New ESC-EACTS guidelines on myocardial revascularization to be released at EuroPCR 2014
3. EuroPCR 2014 showcases technological advances in complex cardiovascular interventions
4. Personalizing revascularization strategy for STEMI patients is vital, EuroPCR panel finds
5. EuroPCR 2014 examines whether science translates into practice with new session format
6. Study examines medicare use for Mohs micrographic surgery and surgical excision for skin cancer
7. Study examines drug regimen for the treatment of non-small cell lung cancer among older patients
8. Study examines adverse effects among different radiation therapies for prostate cancer
9. LA BioMeds Dr. John Tsuang examines effects of Ibudilast and metamphetamines
10. Study examines benefit of follow-up CT when abdominal ultrasound inconclusive
11. Research examines when benefits of screening mammography outweigh the harms for women in their 40s
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... The Visiting ... the C. R. Bard Foundation, Inc. to support the music therapy ... service available through the nonprofit home care agency. Using evidence-based methods, professionally trained ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne is ... product of her research center at Bio-Logic Aqua Research® Water Life Science®, has ... greatest number of sufferers of blindness. “We think that Nature’s Tears® EyeMist® will ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... cruciate ligament (ACL) offer patients improved quality of life five years after injury, ... Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed patients for ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... in Houston, is pleased to announce their expansion to the Midwest with the ... directors Alysse Hollis and Ronald Bell, and of counsels, John Peck and Robert ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... -- Did you know that PhRMA member companies invested $65.5 billion ... on brand medicines, generics and the supply chain account for 14 ... half of this (7 percent)? Or that the United ... capital investments in high-growth biopharmaceutical startups? ... The biopharmaceutical industry ...
(Date:7/15/2017)... 15, 2017 Enterin Inc., a Philadelphia ... disease (PD), today announced the completion of a $12.7 million ... Ventures III, as well as the participation of existing investors. ... to have the support of New Ventures III and our ... validation of the potential of our platform technology to transform ...
(Date:7/13/2017)... -- RK Logistics Group, Inc. was awarded California ... Fremont, CA headquarters facility where it provides ... San Jose for hi-tech, pharmaceutical and biomedical ... with its Fremont Innovation District, is excited to strategically partner ... to the hundreds of biotech, pharma and biomed companies throughout ...
Breaking Medicine Technology: